Charles Albright is CSO & VP at Editas Medicine, Inc. (EDIT). They have made 13 open-market trades across 1 company since 2018, most recently 2020-12-15.
CIK 0001682323
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EDIT | 24,907 | $59K |
Shares reported on the most recent Form 4, priced at the 2020-12-17 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EDIT | SELL | 2020-12-15 | 2020-12-17 | $63.20 | $1.3M | +21.4% | +14.5% | -26.1% |
| EDIT | SELL | 2020-12-09 | 2020-12-11 | $45.00 | $450K | +35.7% | +27.9% | -21.3% |
| EDIT | SELL | 2020-12-07 | 2020-12-08 | $40.02 | $1.6M | +48.1% | +106.1% | -6.8% |
| EDIT | SELL | 2020-11-09 | 2020-11-10 | $31.21 | $7K | -5.3% | +122.8% | +132.4% |
| EDIT | SELL | 2020-10-15 | 2020-10-16 | $31.39 | $94K | -7.1% | -14.6% | +123.2% |
| EDIT | SELL | 2020-08-17 | 2020-08-19 | $35.29 | $353K | -3.9% | -7.5% | -21.6% |
| EDIT | SELL | 2020-08-06 | 2020-08-10 | $37.41 | $383K | +3.8% | -12.6% | -14.1% |
| EDIT | SELL | 2020-07-15 | 2020-07-17 | $32.22 | $97K | -6.9% | +13.5% | -0.1% |
| EDIT | SELL | 2020-05-06 | 2020-05-08 | $25.28 | $4K | +15.0% | +9.2% | +48.4% |
| EDIT | SELL | 2020-02-07 | 2020-02-10 | $26.95 | $17K | -11.9% | -28.0% | -2.2% |
| EDIT | SELL | 2020-02-03 | 2020-02-04 | $26.54 | $295K | -6.4% | -12.2% | -12.9% |
| EDIT | SELL | 2018-06-13 | 2018-06-15 | $35.98 | $720K | -4.4% | -5.7% | -13.7% |
| EDIT | SELL | 2018-05-23 | 2018-05-25 | $35.00 | $350K | +4.0% | +3.1% | -16.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.